IN8BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
IN8BIO, INC. (INAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-06
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-13 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-14 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-30 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |